There is pretty good preclinical as well as some clinical evidence in Prostate cancer patients that two of the Alpha1 receptor blockers, give improved outcomes in terms of prostate cancer recurrence, progression and even metastasis. The two specific drugs with the strongest evidence are Prazosin and Doxazosin. Both are available generics and both are commonly prescribed for high blood pressure as well as for helping with urinary flow from BPH. This is by means of their primary action of relaxing smooth muscle fibers in blood vessel walls and in the urethra.
But they have multiple other cellular and signaling actions that are likely contributing to their anti-prostate cancer effects. I currently take high blood pressure medications and am not seeing good control. So I plan to switch out one and start either Doxazosin or Prazosin. It is not clear to me which is better since I cannot find them in a trial head-to-head.
Dosing is similar and both require starting very low for the first days then titrating up. Here is some of the research. The first link is a very good review of the mechanisms implicated for prostate cancer.
The role of alpha-blockers in the management of prostate cancer
pubmed.ncbi.nlm.nih.gov/151...
And here is a study (retrospective) of recurrence rates of PC after initial RT. (Thanks to Scout for initially posting this.)
A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated
nature.com/articles/s41598-...
"Prazosin significantly reduced biochemical relapse at both two and five-years (2.72%, 8.84%) compared to control (22.61%, 34.52%). Recurrence free survival was also significantly higher in the prazosin group. This remained after multivariable analysis (HR: 0.09, 95% CI: 0.04–0.26, p < 0.001). Patients receiving prazosin had a 3.9 times lower relative risk of biochemical relapse compared to control."
And an abstract from ASCO on reduction of metastasis 14.4% vs 7.4% over 15 years:
Doxazosin use in prostate cancer patients: Its effect on development of metastases.
ascopubs.org/doi/abs/10.120...
"Results: Of the 941 patients identified with prostate cancer, 121 met the criteria for doxazosin use. Of the 121 patients who used doxazosin, 9 developed metastases (7.4%). Of the 785 patients who did not use doxazosin, 113 developed metastases (14.4%). This difference met statistical significance (p < 0.05). Conclusions: Through stimulation of the EphA2 tyrosine kinase, doxazosin has been shown to decrease the ability of prostate cancer cells to metastasize in an orthotopic xenograft model of human prostate cancer cells5. A 15 year single institution study of prostate cancer patients suggests that doxazosin use was associated with a significantly decreased rate of prostate cancer metastasis."